Clinical Trial Update: Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating response to two induction courses (12 intravesical instillations) of BCG for high-risk superficial bladder cancer; study complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• High-risk Superficial Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guérin (Bacillus Calmette-Guérin)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Bladder Cancer, High Risk Superficial | Phase 2 | Status: COMPLETED | Results posted: 2022-12-29